Nitrated T cell epitope linked vaccine targeting CD47 elicits antitumor immune responses and acts synergistically with vaccine targeting PDL1
International Immunopharmacology · 2024-02 · 128 · 111374
DOI: 10.1016/j.intimp.2023.111374 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Immunopharmacology, 2024-02. Verfasst von Danni Deng und 8 weiteren Autor:innen. Beteiligte Einrichtung: Jiangsu Key Laboratory of Druggability of Biopharmaceuticals and State Key Laboratory of Natural Medicines, School of Life Science and Technology, Ch…. Hauptthemen laut MEDLINE: Neoplasms, Cancer Vaccines. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 48 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Double First Class University Plan.
Abstract (Originalsprache)
Despite the clinical breakthrough made by immune checkpoint blockades (ICB) in cancer immunotherapy, immunosuppressed tumor microenvironment (TME) remains a major impediment in the efficacy of ICB immunotherapy. In this study, we constructed a Nitrated T cell epitope (NitraTh) linked vaccine targeting CD47, namely CD47-NitraTh. CD47-NitraTh could repress the progression of tumor by inducing tumor-specific immune response. Furthermore, combination vaccination with CD47-NitraTh and PDL1-NitraTh could reconstruct tumor associated macrophage, enhance macrophage-mediated phagocytosis for tumor cells, and promote the activation of tumor infiltrating T cells. Notably, by activating chemokine signaling pathway, NitraTh based vaccines reversed immunosuppressed TME, resulting in improved therapeutic outcome for tumor. With the advantage of reversing immunosuppressed TME, NitraTh based vaccine seems an optimal immunotherapy strategy for patients who are not sensitive to antibody based ICB.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Jiangsu Key Laboratory of Druggability of Biopharmaceuticals and State Key Laboratory of Natural Medicines, School of Life Science and Technology, China Pharmaceutical University, Nanjing, Jiangsu, 210009, PR China; Dep…
- Jiangsu Key Laboratory of Druggability of Biopharmaceuticals and State Key Laboratory of Natural Medicines, School of Life Science and Technology, China Pharmaceutical University, Nanjing, Jiangsu, 210009, PR China.
- Department of General Internal Medicine, The First Affiliated Hospital of Xinjiang Medical University, Xinjiang Uyghur Autonomous Region, 830054, PR China.
- Jiangsu Key Laboratory of Druggability of Biopharmaceuticals and State Key Laboratory of Natural Medicines, School of Life Science and Technology, China Pharmaceutical University, Nanjing, Jiangsu, 210009, PR China. Ele…
Förderung
- National Natural Science Foundation of China
- Double First Class University Plan
Zitieren
APA
Deng, D., Li, G., Xia, X., Xu, S., Gao, L., Zhang, L., Yao, W., Tian, H., & Gao, X. (2024). Nitrated T cell epitope linked vaccine targeting CD47 elicits antitumor immune responses and acts synergistically with vaccine targeting PDL1. International Immunopharmacology, 128, 111374. https://doi.org/10.1016/j.intimp.2023.111374
Vancouver
Deng D, Li G, Xia X, Xu S, Gao L, Zhang L, et al. Nitrated T cell epitope linked vaccine targeting CD47 elicits antitumor immune responses and acts synergistically with vaccine targeting PDL1. International Immunopharmacology. 2024;128:111374. doi:10.1016/j.intimp.2023.111374
BibTeX
@article{Deng2024,
author = {Deng, Danni and Li, Guozhi and Xia, Xuefei and Xu, Shuyang and Gao, Le and Zhang, Li and Yao, Wenbing and Tian, Hong and Gao, Xiangdong},
title = {Nitrated T cell epitope linked vaccine targeting CD47 elicits antitumor immune responses and acts synergistically with vaccine targeting PDL1},
journal = {International Immunopharmacology},
year = {2024},
volume = {128},
pages = {111374},
doi = {10.1016/j.intimp.2023.111374}
}
EUVIMED